GRAL Competitors & Alternatives
Compare GRAIL, LLC with similar stocks in the same industry
Diagnostics & Research
GRAL
Main Stock$132.56
Tradestie Score
34
Market Cap
$2.24B
Revenue Growth
0.3%
Analyst Upside
-26.5%
Top Competitors
35 stocks in Diagnostics & Research| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
QGEN
QIAGEN N.V.
|
$42.04
|
$10.04B | 22.6 | 52 | Compare |
|
RVMD
Revolution Medicines, Inc. Common Stock
|
$205.89
|
$8.57B | - | 53 | Compare |
|
CRL
Charles River Laboratories International, Inc.
|
$286.83
|
$8.39B | - | 44 | Compare |
|
GH
Guardant Health, Inc. Common Stock
|
$174.75
|
$7.81B | - | 46 | Compare |
|
RDNT
RadNet, Inc. Common Stock
|
$67.70
|
$6.00B | - | 39 | Compare |
|
BLLN
BLLN
|
$105.76
|
$5.02B | 149.9 | 35 | Compare |
|
SHC
Sotera Health Company Common Stock
|
$18.12
|
$4.60B | 32.4 | 54 | Compare |
|
WGS
GeneDx Holdings Corp. Class A Common Stock
|
$70.96
|
$3.26B | - | 57 | Compare |
|
VCYT
Veracyte, Inc.
|
$44.19
|
$2.85B | 32.9 | 37 | Compare |
|
ADPT
Adaptive Biotechnologies Corporation Common Stock
|
$27.37
|
$2.22B | - | 49 | Compare |
More GRAL Analysis
Data updated: Oct 01, 2026 | Industry: Diagnostics & Research (SIC 8071)
35 stocks in this industry